Assessment of genotoxicity of two anti-Parkinsonian drugs (selegiline hydrochloride and bromocryptine mesylate) in vivo in mouse bone marrow cells

Add time:09/10/2019    Source:sciencedirect.com

Selegiline hydrochloride (1-deprenyl) and bromocryptine mesylate (2-bromo-α-ergocryptine) are two drugs that have shown considerable promise in the treatment of Parkinson's disease. The in vivo mouse bone marrow micronucleus assay was used to examine their clastogenic and cytotoxic potential in human clinical dose range. Our results indicate that both drugs failed to induce significant number of micronuclei and were not cytotoxic at any of the doses tested, in vivo in mouse bone marrow cells, at doses as high as 16-times the clinical dose used in humans.

We also recommend Trading Suppliers and Manufacturers of dl-Cathinone Hydrochloride (cas 16735-19-6). Pls Click Website Link as below: cas 16735-19-6 suppliers

Prev:Case ReportA two fatal cases of poisoning involving new cathinone derivative PV8
Next:Chiral and stable isotope analysis of synthetic cathinones)